Navigation Links
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:4/29/2009

CHADDS FORD, Pa., April 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the first quarter of 2009, including results beginning on February 23, 2009 for Indevus Pharmaceuticals, which Endo acquired during the quarter.

Net sales during the first quarter of 2009 increased 16% to $335.3 million compared with $290.3 million in the first quarter of 2008. Net income for the three months ended March 31, 2009 was $39.0 million compared with $59.5 million in the comparable 2008 period. As detailed in the Supplemental Financial Information below, adjusted net income for the three months ended March 31, 2009 was $79.0 million compared with $68.2 million in the same period in 2008.

Diluted earnings per share for the three months ended March 31, 2009 were $0.33 compared with $0.44 in the first quarter of 2008. Adjusted diluted earnings per share for the three months ended March 31, 2009 were $0.67 compared with $0.51 in the same period in 2008.

"We had a solid first quarter during which we diversified our commercial business beyond pain management, reorganized our sales and marketing and R&D groups, and repositioned our company for sustainable future growth," said Dave Holveck, president and chief executive officer of Endo Pharmaceuticals. "I believe our broader therapeutic focus on urology and oncology and more capable specialty infrastructure will enable us to meet aggressive long-term growth targets and adapt quickly to a changing healthcare environment."

Selected Product Review

PAIN PRODUCTS

LIDODERM(R): For the quarter ended March 31, 2009, net sales of LIDODERM decreased 5% to $171.6 million compared with $180.5 million in the same period a year ago. Prescription volume for LIDODERM decrease
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... November 23, 2014 This evaluation ... as its significance, programs and manufacturing technological innovation. ... suppliers major market gamers in information. In this ... specifications, prospective, manufacturing value, and 2009-2014 market shares ... evaluation symbolizes the globally and Chinese suppliers finish ...
(Date:11/23/2014)... 23, 2014 Asher Milgrom, is ... & Wellness was recently featured on International ... president and CEO of American Medical Aesthetics & Wellness, ... received a full scholarship to attend an M.D./Ph.D program ... at the University of Chicago, where his field of ...
(Date:11/23/2014)... 2014 BambooFlooringChina.com , the world’s leader ... strand woven bamboo flooring collection. Now, the business is ... company’s CEO, the promotion is valid until Dec. 20, 2014. ... a smooth and dust-free surface, which makes it very easy ... industry, the company wants to make its website the best ...
(Date:11/22/2014)... 23, 2014 PrettyTailor , an ... a new big promotion. Customers can buy new dresses ... customers can visit its website. , As a matter ... occasion dresses. It mainly provides four types of wedding ... and flower girl dresses. It also provides a variety ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 Today, Dylan ... its new collection of wedding dresses; the business offers ... other related accessories for ladies worldwide, allowing them to ... manager of the company, this new collection of chic ... launch. Moreover, they are offered at discounted rates now. ...
Breaking Medicine News(10 mins):Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2
... By Kathleen Doheny HealthDay Reporter , FRIDAY, ... overweight or obese tend to befriend and date people ... The finding echoes previous research that found health ... study author Dr. Tricia M. Leahey, an assistant professor ...
... , FRIDAY, Jan. 14 (HealthDay News) -- Riding in a convertible ... warns. U.S. researchers conducted sound level measurements using five different ... noise levels were above 85 decibels (dB) when the top was ... (mph) or faster. Exposure to noise levels above 85 dB ...
... News) -- Among older adults who,ve recently had a ... to take medications meant to prevent another heart attack, ... Harvard Medical School researchers and colleagues analyzed the pharmacy ... who recently had a heart attack and were prescribed ...
... By Jenifer Goodwin HealthDay Reporter , FRIDAY, Jan. ... in love? Ever feel like the passing years, the never-ending ... have quashed your infatuation for your spouse? New ... to that passion and romance for decades or more. ...
... Amanda Gardner HealthDay Reporter , THURSDAY, Jan. ... that they will lower the maximum amount of the ... as Vicodin and Percocet because of reports of severe ... the upper threshold of acetaminophen in prescription drugs containing ...
... E. coli uses a laser to detect and monitor ... The technique described this month in the International Journal ... incidence of waterborne disease outbreaks. Microbial contamination of water ... are the leading causes of illness and death in the ...
Cached Medicine News:Health News:Overweight Young Adults Often Have Overweight Friends, Sweethearts 2Health News:Overweight Young Adults Often Have Overweight Friends, Sweethearts 3Health News:Riding With the Top Down May Put Hearing at Risk 2Health News:Heart Attack Patients With Kidney Problems Often Skip Meds 2Health News:Brain Scans Show Married Love Can Last 2Health News:Brain Scans Show Married Love Can Last 3Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 2Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 3Health News:Speeding up E. coli detection 2
(Date:11/21/2014)...  Heated dialogue in recent months about the rising ... to Gilead,s new hepatitis C drug Harvoni® – has ... what it means to put a price on patient ... while drug pricing is one of the most debated ... general business and ethical standpoint – it is also ...
(Date:11/21/2014)... , 21. November 2014 ... heute bekannt gegeben, dass die Europäische ... die Kennzeichnung als Orphan-Medizinprodukt an Palovarotene ... Unternehmens zur Behandlung von Fibrodysplasia ossificans ... stark beeinträchtigende genetische Krankheit, die von ...
(Date:11/21/2014)... 20, 2014  Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, announced today that it ... support a strong launch of Edwards Lifesciences Foundation,s new ... improve the global communities where its employees live and ... giving will exceed $8 million, including more than $7 ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2
The K-ASSAY Rheumatoid Factor Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifying...
... Urine Controls are supplied as ... requiring no reconstitution or dilution. ... urine, fortified to target levels ... Preservatives including sodium azide have ...
... Liquid Lipid Control is intended for use ... test sample of known concentration for monitoring ... K-ASSAY Liquid Lipid Control with patient serum ... listed constituents. The user can compare observations ...
The K-ASSAY ITA Lyophilized Multi-Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assays for the li...
Medicine Products: